FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit
New York, New York-- (Newsfile Corp. - February 7, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...
KYTX LAWSUIT ALERT: Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...
Today12d
Walmart gets a new logo and people are talking. Here's why
Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...
The Bakersfield Californian15d
Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...
LOS ANGELES, Jan. 24, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX) investors of a class action representing ...
Nasdaq17d
Kyverna Therapeutics Names Naji Gehchan Chief Medical And Development Officer
(RTTNews) - Kyverna Therapeutics, Inc. (KYTX) a California-based biopharmaceutical company, Tuesday announced the appointment of Naji Gehchan as Chief Medical and Development Officer. Gehchan will ...
MarketWatch17d
Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief
As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the ...
Investing17d
Kyverna Therapeutics appoints new chief medical officer
EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...
abc2717d
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
In connection with the appointment of Dr. Gehchan as Kyverna's Chief Medical and Development Officer, on January 22, 2025, Kyverna will grant Dr. Gehchan an option to purchase 425,000 shares of ...
Mena FN17d
KYTX Investors Have Opportunity To Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX ) pursuant and/or traceable to Kyverna's initial public ...
Mena FN17d
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, As Chief Medical And Development Officer
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...
Investing17d
Kyverna Therapeutics appoints new chief medical officer
EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...